MarketPulse

biotech

124 articles
The Motley FoolThe Motley Fool··Adria Cimino

Market Pullback Presents Entry Points in AI and Life Sciences Leaders

Market volatility creates buying opportunities in AI and biotech leaders Nvidia, Moderna, and Amazon Web Services, each positioned to benefit from industry growth trends.
NVDAAMZNMRNAmarket declinecloud computing
The Motley FoolThe Motley Fool··Josh Kohn-Lindquist

ImmunityBio Gains 41% Following European Approval of Bladder Cancer Therapy

ImmunityBio shares surged 41% after Europe approved its bladder cancer therapy ANKTIVA, enabling commercialization across 30+ nations and opening significant revenue opportunities.
IBRXIOVAKRYSbiotechbladder cancer
BenzingaBenzinga··Vandana Singh

Sensei Biotherapeutics Surges on Faeth Acquisition and $200M Investment

Sensei Biotherapeutics stock surged 230% after acquiring Faeth Therapeutics and securing $200M investment, expanding its oncology pipeline with PIKTOR therapy.
SNSEacquisitionbiotech
The Motley FoolThe Motley Fool··Adria Cimino

Viking Therapeutics Advances Obesity Treatment Pipeline Ahead of 2026 Trial Milestones

Viking Therapeutics advances obesity drug VK2735 through phase 3 trials, expecting 2026 trial data. Dual GIP/GLP-1 agonist targets $100B+ market opportunity.
LLYNVOVKTXbiotechclinical trials